MAPT and Neurofibrillary tangles: Further aggregation of tau proteins into the growing neurofibrillary tangle is prevented by E2814’s binding to this microtubule region. Another DMT in this drug class, TRx0237, is in development and is the chemically reduced form of the most advanced tau protein aggregation inhibitor, methylthioninium [18].